Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence

References

• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424.
   PubMed Web of Science ®Google Scholar
• Jjv M, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Supplement 1):S111–S24.
   PubMed Web of Science ®Google Scholar
• O’Meara E, McDonald M, Chan M, et al. CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis. Can J Cardiol. 2020;36(2):159–169.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019;18(4):295–311.
   PubMed Web of Science ®Google Scholar
• Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365.
   PubMed Web of Science ®Google Scholar
• Schmedt N, Enders D, Walker J, et al. Sodium-glucose Co-transporter 2 inhibitors and the risk of venous thromboembolism in patients with type 2 diabetes: a cohort study. Am J Med. 2020. DOI:10.1016/j.amjmed.2020.10.046
   PubMed Web of Science ®Google Scholar
• Fralick M, Kim SC, Schneeweiss S, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812.
   PubMed Web of Science ®Google Scholar
• Douros A, Lix LM, Fralick M, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med. 2020;173(6):417–425.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014;53(4):295–304.
   PubMed Web of Science ®Google Scholar
• Kabadi U. Marked weight loss, muscle wasting and fatigue on administration of empagliflozin in a subject with type 2 diabetes. Br J Med Med Res. 2017;21(5):1–7.
   Google Scholar
• Gao F, Hall S, Bach LA. Myopathy secondary to empagliflozin therapy in type 2 diabetes. Endocrinology, Diabetes Metab Case Rep. 2020;2020: 20–0017.
   Google Scholar
• Brailovksi E, Kim RB, Juurlink D. Rosuvastatin myotoxicity after starting canagliflozin treatment: a case report. Ann Intern Med. 2020;173(7):585–587.
   Web of Science ®Google Scholar
• Madaan T, Akhtar M, Najmi AK. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: current status and future perspective. Eur J Pharm Sci. 2016;93:244–252.
   PubMed Web of Science ®Google Scholar
• Raje S, Callegari E, Sahasrabudhe V, et al. Novel application of the two-period microtracer approach to determine absolute oral bioavailability and fraction absorbed of ertugliflozin. Clin Transl Sci. 2018;11(4):405–411.
   PubMed Web of Science ®Google Scholar
• FDA - Canagliflozin. 2017. (Accessed 05.02.2021, at 2021 02 05 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204042s026lbl.pdf.)
   Google Scholar
• FDA - Dapagliflozin. 2018. (Accessed 05.02.2021, at 2021 02 05 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202293s015lbl.pdf.)
   Google Scholar
• FDA - Ertugliflozin. 2017. (Accessed 05.02.2021, at 2021 02 05 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf.)
   Google Scholar
• FDA - Empagliflozin. 2016. (Accessed 05. 02.2021,at 2021 02 05 https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s008lbl.pdf.)
   Google Scholar
• Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019;79(10):1135–1146.
   PubMed Web of Science ®Google Scholar
• Ndefo UA, Anidiobi NO, Basheer E, et al. Empagliflozin (jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015;40(6):364–368.
   PubMedGoogle Scholar
• Frampton JE. Empagliflozin: a review in type 2 diabetes. Drugs. 2018;78(10):1037–1048.
   PubMed Web of Science ®Google Scholar
• Fediuk DJ, Nucci G, Dawra VK, et al. Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor. Clin Pharmacokinet. 2020;59(8):949–965.
   PubMed Web of Science ®Google Scholar
• Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018;14(12):1287–1302.
   PubMed Web of Science ®Google Scholar
• Mamidi R, Dallas S, Sensenhauser C, et al. In vitro and physiologically-based pharmacokinetic based assessment of drug–drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017;83(5):1082–1096.
   PubMed Web of Science ®Google Scholar
• Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and human. Drug Metab Disp. 2010;38(3):405–414.
   PubMed Web of Science ®Google Scholar
• FDA - Empagliflozin Pharmacology Reviews. 2013. (Accessed 14.02.2021, at 2021 02 14 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204629Orig1s000PharmR.pdf.)
   Google Scholar
• FDA - Ertugliflozin/Sitagliptin Non-Clinical Reviews. 2016. (Accessed 14.02.2021, at 2021 02 14 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000PharmR.pdf.)
   Google Scholar
• FDA - Canaglifozin Pharmacology Reviews. 2014. (Accessed 21.02.2021, at 2021 02 21 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204353Orig1s000PharmR.pdf.)
   Google Scholar
• Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther. 2003;25(10):2553–2563.
   PubMed Web of Science ®Google Scholar
• McIver LA, Siddique MS. Atorvastatin. StatPearls. Treasure Island (FL): Statpearls publishing copyright © 2020. StatPearls Publishing LLC; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430779/
   Google Scholar
• Toda T, Eliasson E, Ask B, et al. Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol. 2009;105(5):327–332.
   PubMed Web of Science ®Google Scholar
• Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundament Clin Pharmacol. 2005;19(1):117–125.
   PubMed Web of Science ®Google Scholar
• FDA - Simvastatin. 2008. (Accessed 05.02.2021, at 2021 02 05 https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019766s076lbl.pdf.)
   Google Scholar
• Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. J Clin Transl Endocrinol. 2017;8:6–14.
   PubMedGoogle Scholar
• FDA - Pivastatin. 2019. (Accessed 05.02.2021, at 2021 02 05 https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/667/original/FDA_Label_-_Pitavastatin.pdf?1564609735.)
   Google Scholar
• Tubic-Grozdanis M, Hilfinger JM, Amidon GL, et al. Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm Res. 2008;25(7):1591–1600.
   PubMed Web of Science ®Google Scholar
• Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42(13):1141–1160.
   PubMed Web of Science ®Google Scholar
• Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it’s not just about OATP1B1. Clin Pharmacol Ther. 2012;92(5):584–598.
   PubMed Web of Science ®Google Scholar
• Salna MP, Singer HM, Dana AN. Pravastatin-induced eczematous eruption mimicking psoriasis. Case Rep Derm Sci. 2017;2017:3418204.
   Google Scholar
• FDA - Rosuvastatin. 2019. (Accessed 05.02.2021, at 2021 02 05 https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/649/original/FDA_Label_-_Rosuvastatin.pdf?1563989473.)
   Google Scholar
• FDA - Atorvastatin. 2018. (Accessed 05.02.2021, at 2021 02 05 https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/670/original/FDA_Label_-_atorvastatin.pdf?1565199067.)
   Google Scholar
• Foye WO, Lemke TL, Williams DA. Foye’s principles of medicinal chemistry: Philadelphia: Lippincott. Williams & Wilkins; 2008.
   Google Scholar
• Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Disp. 2005;33(4):537–546.
   PubMed Web of Science ®Google Scholar
• Kitamura S, Maeda K, Wang Y, et al. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Disp. 2008;36(10):2014–2023.
   PubMed Web of Science ®Google Scholar
• Fujino H, Saito T, Ogawa S, et al. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2010;57(10):1305–1311.
   Google Scholar
• Matsushima S, Maeda K, Kondo C, et al. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005;314(3):1059–1067.
   PubMed Web of Science ®Google Scholar
• Bogman K, Peyer AK, Török M, et al. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol. 2001;132(6):1183–1192.
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Zolk O, Fromm MF, et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009;86(2):197–203.
   PubMed Web of Science ®Google Scholar
• Karibe T, Hagihara-Nakagomi R, Abe K, et al. Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates. Pharm Res. 2015;32(5):1634–1647.
   PubMed Web of Science ®Google Scholar
• Ho RH, Tirona RG, Leake BF, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006;130(6):1793–1806.
   PubMed Web of Science ®Google Scholar
• Knauer MJ, Urquhart BL, Meyer Zu Schwabedissen HE, et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010;106(2):297–306.
   PubMed Web of Science ®Google Scholar
• Kameyama Y, Yamashita K, Kobayashi K, et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005;15(7):513–522.
   PubMed Web of Science ®Google Scholar
• Vildhede A, Karlgren M, Svedberg EK, et al. Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. Drug Metab Disp. 2014;42(7):1210–1218.
   PubMed Web of Science ®Google Scholar
• Grube M, Köck K, Oswald S, et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther. 2006;80(6):607–620.
   PubMed Web of Science ®Google Scholar
• Noé J, Portmann R, Brun M-E, et al. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Disp. 2007;35:1308–1314.
   PubMed Web of Science ®Google Scholar
• Varma MV, Rotter CJ, Chupka J, et al. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011;8(4):1303–1313.
   PubMedGoogle Scholar
• Hirano M, Maeda K, Shitara Y, et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004;311(1):139–146.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112(1):71–105.
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Chang M, Liu X, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012;29(2):163–177.
   PubMed Web of Science ®Google Scholar
• Devineni D, Manitpisitkul P, Murphy J, et al. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants. Clin Pharmacol Drug Dev. 2015;4(3):226–236.
   PubMed Web of Science ®Google Scholar
• Macha S, Lang B, Pinnetti S, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther. 2014;52(11):973–980.
   PubMed Web of Science ®Google Scholar
• Dawra VK, Cutler DL, Zhou S, et al. Assessment of the drug interaction potential of ertugliflozin with sitagliptin, metformin, glimepiride, or simvastatin in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(3):314–325.
   PubMed Web of Science ®Google Scholar
• Gupta R, Alcantara R, Popli T, et al. Myopathy associated with statins and SGLT2 - A review of literature. Curr Probl Cardiol. 2020;46(4):100765.
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.
   PubMed Web of Science ®Google Scholar
• Tsurutani Y, Nakai K, Inoue K, et al. Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: a multicentre, randomized, prospective, open-label, active-controlled study. Diabetes Obes Metab. 2018;20(11):2675–2679.
   PubMed Web of Science ®Google Scholar
• Yabe D, Nishikino R, Kaneko M, et al. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf. 2015;14(6):795–800.
   PubMed Web of Science ®Google Scholar
• Cavender MA, Norhammar A, Birkeland KI, et al. SGLT-2 inhibitors and cardiovascular risk: An analysis of CVD-REAL. J Am Coll Cardiol. 2018;71(22):2497–2506.
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with sglt-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628–2639.
   PubMed Web of Science ®Google Scholar
• Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report (Altmetric). 2020. (Accessed 22.02.2021, at 2021 02 22 https://annals.altmetric.com/details/87107244.)
   Google Scholar
• Hennessy S, Leonard CE, Gagne JJ, et al. Pharmacoepidemiologic methods for studying the health effects of drug-drug interactions. Clin Pharmacol Ther. 2016; 99(1): 92–100.
   PubMed Web of Science ®Google Scholar
• Damania D, Leuva H, Khan Z, et al. 429: rhabdomyolysis secondary to diabetic ketoacidosis. Crit Care Med. 2018;46(1):198.
   Web of Science ®Google Scholar
• Wang LM, Tsai ST, Ho LT, et al. Rhabdomyolysis in diabetic emergencies. Diabetes Res Clin Pract. 1994;26(3):209–214.
   PubMed Web of Science ®Google Scholar